Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 354

1.

Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.

Bösmüller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F.

Hum Pathol. 2013 Mar;44(3):329-35. doi: 10.1016/j.humpath.2012.07.010.

PMID:
23089489
2.

Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.

Hayashi Y, Sasaki H, Takeshita S, Nishikawa R, Nishikawa H, Arakawa A, Yamashita Y, Takahashi S, Sugiura-Ogasawara M.

Oncol Rep. 2014 Nov;32(5):1815-9. doi: 10.3892/or.2014.3442.

PMID:
25174456
3.

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.

Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A.

Acta Neuropathol. 2011 Jul;122(1):11-9. doi: 10.1007/s00401-011-0841-z.

PMID:
21638088
4.

Expression of BRAF V600E mutant protein in epithelial ovarian tumors.

Preusser M, Capper D, Berghoff AS, Horvat R, Wrba F, Schindl M, Schoppmann SF, von Deimling A, Birner P.

Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):159-64. doi: 10.1097/PAI.0b013e31825d7402.

PMID:
22820660
5.

Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.

Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP.

Virchows Arch. 2013 Nov;463(5):623-31. doi: 10.1007/s00428-013-1492-3.

PMID:
24085553
6.

Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.

Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP.

Hum Pathol. 2013 Nov;44(11):2563-70. doi: 10.1016/j.humpath.2013.06.018.

PMID:
24071017
7.

Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.

Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA.

Am J Surg Pathol. 2013 Mar;37(3):413-20. doi: 10.1097/PAS.0b013e318271249e.

PMID:
23211290
8.

Loss of p16INK4A expression in low-grade ovarian serous carcinomas.

Schlosshauer PW, Deligdisch L, Penault-Llorca F, Fatemi D, Qiao R, Yao S, Pearl M, Yang Z, Sheng T, Dong J.

Int J Gynecol Pathol. 2011 Jan;30(1):22-9. doi: 10.1097/PGP.0b013e3181ed89b3. Erratum in: Int J Gynecol Pathol. 2011 May;30(3):314.

PMID:
21131838
9.

Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.

Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, Kurman RJ, Wang TL, Shih IeM.

Clin Cancer Res. 2004 Oct 1;10(19):6432-6.

10.

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.

Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IeM.

J Pathol. 2014 Jan;232(1):16-22. doi: 10.1002/path.4293.

11.

Molecular characterization of 103 ovarian serous and mucinous tumors.

Vereczkey I, Serester O, Dobos J, Gallai M, Szakács O, Szentirmay Z, Tóth E.

Pathol Oncol Res. 2011 Sep;17(3):551-9. doi: 10.1007/s12253-010-9345-8.

PMID:
21136228
12.

Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.

Brown NA, Betz BL, Weigelin HC, Elenitoba-Johnson KS, Lim MS, Bailey NG.

Am J Clin Pathol. 2015 Jan;143(1):89-99. doi: 10.1309/AJCPDN4Q1JTFGCFC.

PMID:
25511147
13.
14.
15.

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA.

Am J Surg Pathol. 2013 Jan;37(1):61-5. doi: 10.1097/PAS.0b013e31826485c0.

PMID:
23026937
16.
17.

Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.

Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D.

Am J Surg Pathol. 2012 Dec;36(12):1796-800. doi: 10.1097/PAS.0b013e3182549b50.

PMID:
22531170
18.

Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.

Liu H, Li Z, Wang Y, Feng Q, Si L, Cui C, Guo J, Xue W.

Pathol Int. 2014 Dec;64(12):601-6. doi: 10.1111/pin.12215.

PMID:
25359093
19.

Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.

Lasota J, Kowalik A, Wasag B, Wang ZF, Felisiak-Golabek A, Coates T, Kopczynski J, Gozdz S, Miettinen M.

Am J Surg Pathol. 2014 Sep;38(9):1235-41. doi: 10.1097/PAS.0000000000000229.

20.

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.

J Pathol. 2013 Dec;231(4):449-56. doi: 10.1002/path.4252.

Supplemental Content

Support Center